All News

RheumNow Podcast square

RheumNow Podcast – BandAids for Rheumatologists (5.14.2021)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com - a website for rheumatologists, by rheumatologists.



We love Rheumatology!

Read Article
RNL, over, microphone

RheumNow Live 2021 Now Available for All

Jack Cush, MD

RheumNow Live (RNL) for 2021 was held March 20 - 21 in Fort Worth, TX, and now all can partake in the meeting - by video, podcast or by signing up for Tuesday Nite Rheumatology (TNR).

Read Article
RheumNow Podcast square

RheumNow Podcast – Falling or Falling in Love?

Jack Cush, MD

Dr. Jack Cush reviews the best journal articles from the past week on RheumNow.com.

Read Article
RheumNow Podcast square

RheumNow Podcast – Uppers and Downers

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Read Article
Novel Results from the @rheum_covid register in #RA patients presented by @jeffsparks #OP0006 Higher risk for patients on rituximab or on JAK inhibitors for hospitalisation & ventilation or death after #COVID19 infection compared to TNFi users. #EULAR2021 @RheumNow https://t.co/40h5zVpxAO
Paul Studenic Stiddyo ( View Tweet)
Excellent job by @jeffsparks @zach_wallace_md @rheum_covid on Abs#0P0006 at #EULAR2021. ⭐️RTX and JAKi: increased COVID severity, not seen in IL-6 or ABA. Critical findings, but confounding role of co-morbidities/ILD/cancer, esp in RTX patients? @RheumNow

Eric Dein ejdein1 ( View Tweet)

Yes more lab abnormalities in #Upadactinib vs #Adalimumab in RA RCTs including cytopenias, transaminitis but not creatinine @RheumNow @eular_org #EULAR2021 but no diff in treatmt emergent Adverse events abst OP0128 Yes do labs when on #Upadacitinib https://t.co/5ypKGxuE3U https://t.co/XRjr0gDnIT

Links:

Janet Pope Janetbirdope ( View Tweet)
Do you really needs to follow labs for pts on #JAKi ? @eular_org #EULAR2021 OP0128 studied 4.5 years in #upadacitinb 6 RCTs in RA. More grade3 or 4 anemia, low lymph, neutrophils & ⬆️

Janet Pope Janetbirdope ( View Tweet)

To clot or NOT? Real world data usually show no ⬆️ VTE in RA with #Jaki compares to other advanced therapies. Diff from high CV risk pts in Oral Surveillance where Tofacitinib had higher VTE vs TNFi @AbbVie symposium @eular_org #EULAR2021 @RheumNow Hard to reconcile diff risk. https://t.co/AWY2zZPSIb
Janet Pope Janetbirdope ( View Tweet)
Andrew Ostor @AbbVie symposium @eular_org presented HZ vaccines are safe in RA pts with #JAKi but with Recombinant HZ vaccine humeral response - 75% in RA pts in JAKi vs 100% controls. So should we hold JAKi with Shringix & if so for 1 or 2 wks? #EULAR2021 @RheumNow https://t.co/wVOFMa9fLm
Janet Pope Janetbirdope ( View Tweet)
Lifetime risk of HZ is 30%! ⬆️ in pts with immune diseases or immunesuppression. All #JAKI ⬆️ risk maybe doubling but NNH & NNT give context. UPA Rx in active RA -20 more pts in remission vs 1 excess HZ if comparing UPA to ADA in RA @RheumNow #EULAR2021 AbbVie symposium https://t.co/14i0IsIpzs
Janet Pope Janetbirdope ( View Tweet)

Do you think JAKi cause VTE? @eular_org @RheumNow #EULAR2021

Janet Pope Janetbirdope ( View Tweet)

Do you think #JAKI ⬆️ #MACE cardiovascular events vs TNFi? @eular_org @RheumNow #EULAR2021

Janet Pope Janetbirdope ( View Tweet)

JAK inhibitor helping vitiligo? Results from phase 3 TRuE-V trial ruxolitinib cream in adolescent/adult vitiligo pts - showed significantly more RUX pts with 75% improvement in facial vitiligo area scoring index (F-VASI75) compared to control at Week 24 https://t.co/q98CBjfdQi

Links:

Dr. John Cush RheumNow ( View Tweet)

Johns Hopkins researchers suggest that treating refractory dermatomyositis with a JAK inhibitor may improve calcinosis. Based on 3 case reports, who had either NXP2 or TIF-1γ refractory DM, all improved their skin, muscle dz and calcinosis. https://t.co/P5k5y0HS6A

Links:

Dr. John Cush RheumNow ( View Tweet)

Real world comparision of baricitinib (n 138) and tofacitinib (n 156) in #RA patients shows at wk 24, BARI out performed TOFA - CDAI remission (40.4 vs 28.3%) and CDAI LDA (81.6 vs 69.3%); safety signals were equal between groups. https://t.co/0quNNGB18K

Links:

Dr. John Cush RheumNow ( View Tweet)

Drug interactions w/ JAK inhibitors - Retrospective analysis of 152,853 pts found ~10% that could have interaction w/ strong OAT3 inhib (<0.1%), CYP3A4 (3%) or CYP3A4 and CYP2C19 inhib (11%) (like lovastatin, prozac, amiodarone, EES, Diflucan) https://t.co/tZztU6cddb

Links:

Dr. John Cush RheumNow ( View Tweet)

Lilly has reported clinical success with Baricitinib (JAK inhibitor) in patients with alopecia. Two studies (BRAVE-AA1 and BRAVE-AA2) show statistically significant improvement in scalp hair regrowth with baricitinib compared to placebo. https://t.co/D0GE2cSzDZ

Links:

Dr. John Cush RheumNow ( View Tweet)

Metanalysis of IBD studies finds combo biologics may have efficacy in refractor IBD. 279 IBD pts Rx w/ dual biologic or JAKi Rx . Most common = TNFi + anti-integrins (48%), ustekinumab & integrins (19%); remission seen in 59% & 34%, higher w/ EIM https://t.co/RReyRuNXck

Links:

Dr. John Cush RheumNow ( View Tweet)

Dr. Olga Petryna ( @drpetryna) weighing the future Rx in RA by Dr. Fleischmann: -CD22, new IL6i & GM-CSF show promises but far form being available -bDMARD or tsDMARD after MTX but work better wMTX -JAKS better choice for mono-therapy but safety is a concern #RNL2021

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×